Apogee Therapeutics Inc [APGE] stock is trading at $75.5, up 1.27%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The APGE shares have gain 7.26% over the last week, with a monthly amount glided 40.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on November 03, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $109. Previously, Mizuho started tracking the stock with Outperform rating on October 21, 2025, and set its price target to $105. On September 25, 2025, RBC Capital Mkts initiated with an Outperform rating and assigned a price target of $60 on the stock. BTIG Research reiterated its Buy rating and increased its price target to $115 on July 07, 2025. Citigroup initiated its recommendation with a Buy and recommended $95 as its price target on March 13, 2025. Canaccord Genuity started tracking with a Buy rating for this stock on November 25, 2024, and assigned it a price target of $89. In a note dated May 10, 2024, BofA Securities initiated a Buy rating and provided a target price of $80 on this stock.
Apogee Therapeutics Inc [APGE] stock has fluctuated between $26.20 and $74.99 over the past year. Currently, Wall Street analysts expect the stock to reach $84.5 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $75.5 at the most recent close of the market. An investor can expect a potential return of 11.92% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.35 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 73.67 points at the first support level, and at 71.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 77.16, and for the 2nd resistance point, it is at 78.83.
Ratios To Look Out For
For context, Apogee Therapeutics Inc’s Current Ratio is 15.86. Also, the Quick Ratio is 15.86, while the Cash Ratio stands at 3.17.
Transactions by insiders
Recent insider trading involved JANE HENDERSON, Officer, that happened on Dec 04 ’25 when 1500.0 shares were purchased. Officer, CARL DAMBKOWSKI completed a deal on Dec 04 ’25 to buy 10900.0 shares. Meanwhile, Chief Financial Officer Henderson Jane sold 1500.0 shares on Nov 25 ’25.
